Valneva SE (VLA.PA)
EUR 1.83
(2.93%)
EUR 1.83
(2.93%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 341.14 Million EUR | -15.04% |
| 2022 | 401.54 Million EUR | -37.92% |
| 2021 | 646.77 Million EUR | 73.98% |
| 2020 | 371.74 Million EUR | 186.9% |
| 2019 | 129.57 Million EUR | 49.41% |
| 2018 | 86.72 Million EUR | -10.3% |
| 2017 | 96.67 Million EUR | -9.51% |
| 2016 | 106.83 Million EUR | -18.36% |
| 2015 | 130.85 Million EUR | 26.95% |
| 2014 | 103.07 Million EUR | -6.54% |
| 2013 | 110.28 Million EUR | 301.41% |
| 2012 | 27.47 Million EUR | -15.83% |
| 2011 | 32.63 Million EUR | -7.31% |
| 2010 | 35.21 Million EUR | 50.31% |
| 2009 | 23.42 Million EUR | 67.7% |
| 2008 | 13.96 Million EUR | 32.1% |
| 2007 | 10.57 Million EUR | 3.03% |
| 2006 | 10.26 Million EUR | 4.48% |
| 2005 | 9.82 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 313.6 Million EUR | -8.07% |
| 2024 Q2 | 300.29 Million EUR | -4.24% |
| 2023 Q1 | 385.21 Million EUR | -4.07% |
| 2023 Q3 | 363.01 Million EUR | 3.17% |
| 2023 FY | 341.14 Million EUR | -15.04% |
| 2023 Q4 | 341.14 Million EUR | -6.03% |
| 2023 Q2 | 351.86 Million EUR | -8.66% |
| 2022 Q3 | 533.1 Million EUR | -15.63% |
| 2022 Q4 | 401.54 Million EUR | -24.68% |
| 2022 FY | 401.54 Million EUR | -37.92% |
| 2022 Q1 | 629.3 Million EUR | -2.7% |
| 2022 Q2 | 631.85 Million EUR | 0.4% |
| 2021 Q2 | 668.03 Million EUR | 28.04% |
| 2021 Q4 | 646.77 Million EUR | 0.0% |
| 2021 Q1 | 521.75 Million EUR | 40.35% |
| 2021 FY | 646.77 Million EUR | 73.98% |
| 2020 Q4 | 371.74 Million EUR | -0.46% |
| 2020 Q1 | 143.41 Million EUR | 10.69% |
| 2020 Q2 | 278.29 Million EUR | 94.04% |
| 2020 Q3 | 373.45 Million EUR | 34.2% |
| 2020 FY | 371.74 Million EUR | 186.9% |
| 2019 Q4 | 129.57 Million EUR | 8.86% |
| 2019 FY | 129.57 Million EUR | 49.41% |
| 2019 Q3 | 119.02 Million EUR | 1.36% |
| 2019 Q2 | 117.41 Million EUR | 12.3% |
| 2019 Q1 | 104.55 Million EUR | 20.56% |
| 2018 FY | 86.72 Million EUR | -10.3% |
| 2018 Q1 | 91.78 Million EUR | -5.06% |
| 2018 Q3 | 85.61 Million EUR | -4.38% |
| 2018 Q4 | 86.72 Million EUR | 1.3% |
| 2018 Q2 | 89.53 Million EUR | -2.45% |
| 2017 Q2 | 100.05 Million EUR | 0.96% |
| 2017 Q1 | 99.1 Million EUR | -7.23% |
| 2017 Q4 | 96.67 Million EUR | 1.21% |
| 2017 FY | 96.67 Million EUR | -9.51% |
| 2017 Q3 | 95.52 Million EUR | -4.54% |
| 2016 Q1 | 107.58 Million EUR | -17.78% |
| 2016 Q2 | 105.51 Million EUR | -1.92% |
| 2016 Q3 | 105.38 Million EUR | -0.13% |
| 2016 Q4 | 106.83 Million EUR | 1.37% |
| 2016 FY | 106.83 Million EUR | -18.36% |
| 2015 Q4 | 130.85 Million EUR | 1.35% |
| 2015 FY | 130.85 Million EUR | 26.95% |
| 2015 Q2 | 132.11 Million EUR | -0.06% |
| 2015 Q1 | 132.19 Million EUR | 28.25% |
| 2015 Q3 | 129.1 Million EUR | -2.28% |
| 2014 Q2 | 102.47 Million EUR | -1.53% |
| 2014 FY | 103.07 Million EUR | -6.54% |
| 2014 Q4 | 103.07 Million EUR | -0.4% |
| 2014 Q3 | 103.48 Million EUR | 0.98% |
| 2014 Q1 | 104.07 Million EUR | -5.63% |
| 2013 FY | 110.28 Million EUR | 301.41% |
| 2013 Q1 | - EUR | -100.0% |
| 2013 Q2 | 124.06 Million EUR | 0.0% |
| 2013 Q3 | 90.94 Million EUR | -26.69% |
| 2013 Q4 | 110.28 Million EUR | 21.25% |
| 2012 Q4 | 27.47 Million EUR | 0.0% |
| 2012 Q2 | 27.22 Million EUR | 0.0% |
| 2012 FY | 27.47 Million EUR | -15.83% |
| 2011 FY | 32.63 Million EUR | -7.31% |
| 2011 Q4 | 32.63 Million EUR | 0.0% |
| 2011 Q2 | 37.62 Million EUR | 0.0% |
| 2010 FY | 35.21 Million EUR | 50.31% |
| 2010 Q4 | 35.21 Million EUR | 0.0% |
| 2010 Q2 | 38.03 Million EUR | 0.0% |
| 2009 FY | 23.42 Million EUR | 67.7% |
| 2009 Q4 | 23.42 Million EUR | 0.0% |
| 2008 FY | 13.96 Million EUR | 32.1% |
| 2007 FY | 10.57 Million EUR | 3.03% |
| 2006 FY | 10.26 Million EUR | 4.48% |
| 2005 FY | 9.82 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ABIONYX Pharma SA | 6.91 Million EUR | -4835.532% |
| ABIVAX Société Anonyme | 131.05 Million EUR | -160.312% |
| Adocia SA | 31.87 Million EUR | -970.424% |
| Aelis Farma SA | 13.08 Million EUR | -2508.135% |
| Biophytis S.A. | 15.84 Million EUR | -2052.464% |
| Advicenne S.A. | 24.37 Million EUR | -1299.45% |
| genOway Société anonyme | 14.45 Million EUR | -2259.305% |
| IntegraGen SA | 5.97 Million EUR | -5604.943% |
| Medesis Pharma S.A. | 6.42 Million EUR | -5208.656% |
| Neovacs S.A. | 3.71 Million EUR | -9089.995% |
| NFL Biosciences SA | 3.62 Million EUR | -9322.09% |
| Plant Advanced Technologies SA | 6.78 Million EUR | -4929.878% |
| Quantum Genomics Société Anonyme | 3.31 Million EUR | -10206.132% |
| Sensorion SA | 13.22 Million EUR | -2479.096% |
| Theranexus Société Anonyme | 5.01 Million EUR | -6700.86% |
| TME Pharma N.V. | 2.78 Million EUR | -12149.336% |
| Valbiotis SA | 13.7 Million EUR | -2388.649% |
| TheraVet SA | 1.48 Million EUR | -22872.768% |
| Valerio Therapeutics Société anonyme | 20.46 Million EUR | -1566.719% |
| argenx SE | 402.79 Million EUR | 15.306% |
| BioSenic S.A. | 32.26 Million EUR | -957.352% |
| Celyad Oncology SA | 9.97 Million EUR | -3318.962% |
| DBV Technologies S.A. | 38.74 Million USD | -780.478% |
| Galapagos NV | 1.56 Billion EUR | 78.157% |
| Genfit S.A. | 105.92 Million EUR | -222.074% |
| GeNeuro SA | 20.13 Million EUR | -1593.871% |
| Hyloris Pharmaceuticals SA | 8.61 Million EUR | -3861.263% |
| Innate Pharma S.A. | 132.29 Million EUR | -157.872% |
| Inventiva S.A. | 101.59 Million EUR | -235.795% |
| MaaT Pharma SA | 22.46 Million EUR | -1418.558% |
| MedinCell S.A. | 77.77 Million EUR | -338.658% |
| Nanobiotix S.A. | 95.74 Million EUR | -256.323% |
| Onward Medical N.V. | 25.69 Million EUR | -1227.512% |
| Oryzon Genomics S.A. | 25.12 Million EUR | -1257.76% |
| OSE Immunotherapeutics SA | 59.07 Million EUR | -477.437% |
| Oxurion NV | 19.73 Million EUR | -1628.537% |
| Pharming Group N.V. | 228.28 Million EUR | -49.438% |
| Poxel S.A. | 53.9 Million EUR | -532.908% |
| GenSight Biologics S.A. | 34.72 Million EUR | -882.36% |
| Transgene SA | 26.51 Million EUR | -1186.511% |
| Financière de Tubize SA | 123.65 Million EUR | -175.895% |
| UCB SA | 6.56 Billion EUR | 94.803% |
| Vivoryon Therapeutics N.V. | 4.54 Million EUR | -7402.617% |